Back to search

Democritus University of Thrace (DUTH)

Ερευνητική μελέτη της τοπικής απάντησης σε επιφανειακό καρκίνο της ουροδόχου κύστης μετά από χορήγηση ανοσοτροποποιητικών παραγόντων

Abstract

dc:description

The analysis that was presented in detail at the clinical and experimental segment of the present thesis constitutes a thorough appraisal of the diverse aspects of the local response of superficial bladder cancer to the intravesical administration of immunomodulatory agents. Therefore, it became possible to draw a number of useful conclusions, and at the same time answers to a number of questions regarding the place and value of biologic response modifiers in the treatment of bladder cancer, as well as the understanding of their mechanism of action. A timely combined regimen consisting of low-dose BCG (5/3x108 CFU) mixed with high-dose interferon-alpha (100 MIU), which is currently under discussion in the literature, seemed to provide equal therapeutic benefit with the classic BCG regimen in all types of bladder tumors. Initial response rates were similar and so was mid-term disease-- free survival for both regimens. Overall, initial response for the combination regimens was 76.9% versus 77,4% for BCG monotherapy, and 12- month cancer free survival reached 87,5% for the combined BCG and IFN-α regimen in contrast to 66,8% for BCG. The combined immunotherapeutic approach resulted in better cumulative disease-free survival than BCG, as determined by Kaplan-Meier analysis, which was very close to statistical significance. Administration of the combination treatment to patients that failed an induction cycle of BCG was proven of equal effectiveness with a second bout of BCG, and uniformly resulting in higher late response rates and longer disease-free intervals, as well as a better overall survival that is significantly improved compared to BCG. It seems that a trend does exist for a superiority of the combination regimen in BCG-refractory cases, and this trend could reach statistical significance in a higher-power study. At the moment, it is accepted that no guideline can be formulated as to the combination of BCG and interferon- alpha in high-risk bladder tumors or BCG-refractory cases. Such an issue will be addressed by prospective randomized controlled studies that are already underway. Disease progression, i.e. invasion of the bladder musculature, was seen equally among patients receiving either the combination regimen, or the BCG monotherapy (3.2% versus 2.5%), but no statistical analysis was attempted because of the limited patient sample. Interferon-alpha monotherapy resulted in poor clinical efficacy. Initial response rate was 38,1% and disease-free survival was 29,08 weeks being significantly less than BCG. Treatment failures with interferonalpha occurred mainly in T1 tumors, as well as in tumors grade 1 and 2. Moreover, interferon-alpha monotherapy was proven almost uniformly less effective than the combined BCG and interferon-alpha regimen. Impaired production of cytokines, as basic components of the local immune response, was also demonstrated in the experimental segment of the study for this type of immunotherapy. It is concluded that the intravesical administration of this agent seems unjustifiable for tumors stage T1 independent of histological differentiation, and also in TaG3 tumors because of their poor cellular differentiation. An indication for interferonalpha monotherapy could be highly recurrent Ta tumors of low or intermediate grade in patients with a history of severe allergic reactions to BCG or serious complications of BCG treatment (systemic toxicity, bladder contracture). Intravesical administration of interferon-alpha in CIS was not studied herein. Nevertheless, the poor efficacy that was clearly demonstrated for IFN-α can lead to the assumption that it would perform the same for CIS. The issue of disease progression was not addressed because of the limited patient sample.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2004

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Zoumpos, Ioannis
  • Ζούμπος, Ιωάννης

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/17430

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Zoumpos, Ioannis; Ζούμπος, Ιωάννης. Ερευνητική μελέτη της τοπικής απάντησης σε επιφανειακό καρκίνο της ουροδόχου κύστης μετά από χορήγηση ανοσοτροποποιητικών παραγόντων. Democritus University of Thrace (DUTH), 2004. http://hdl.handle.net/10442/hedi/17430